Thrombosis restriction for JAK inhibitor in ulcerative colitis

The US Food and Drug Administration has restricted the use of high-dose tofacitinib (Xeljanz) in ulcerative colitis and added a black box warning to the label after researchers found a link between the 10 mg dose and a higher risk of pulmonary embolism (PE) and death in patients with rheumatoid arthritis (RA). In a safety ...

Already a member?

Login to keep reading.

© 2021 the limbic